GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.
SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...
Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...
New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed ...
The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.
Their findings are based on data for 20,146 adults (average age 65; 73% men) with type 2 diabetes and a history of kidney stones, gout, or both, who had not previously used SGLT-2 inhibitors, GLP ...
Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an SGLT2 inhibitor during the post-trial period, they wrote in the New ...
In an emulated clinical trial that included a national cohort of veterans with both type 2 diabetes and CKD, SGLT2 inhibitor use was significantly associated with a lower risk for CKD progression.
Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity. (HealthDay News) — From 2010 to 2023, there was an ...
Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on ...
SGLT-2 inhibitors (which stands for sodium-glucose ... Semaglutide, better known by the trade name Ozempic, is a member of ...
Normally, filtered glucose is about 125 mg/min. Main action of SGLT2 inhibitors is the induction of glucosuria and osmotic diuresis. SGLT2 inhibitors reduce effectively fasting and postprandial ...